1. Home
  2. NVO vs NFLX Comparison

NVO vs NFLX Comparison

Compare NVO & NFLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVO
  • NFLX
  • Stock Information
  • Founded
  • NVO 1923
  • NFLX 1997
  • Country
  • NVO Denmark
  • NFLX United States
  • Employees
  • NVO N/A
  • NFLX N/A
  • Industry
  • NVO Biotechnology: Biological Products (No Diagnostic Substances)
  • NFLX Consumer Electronics/Video Chains
  • Sector
  • NVO Health Care
  • NFLX Consumer Discretionary
  • Exchange
  • NVO Nasdaq
  • NFLX Nasdaq
  • Market Cap
  • NVO 530.0B
  • NFLX 429.1B
  • IPO Year
  • NVO N/A
  • NFLX 2002
  • Fundamental
  • Price
  • NVO $69.03
  • NFLX $928.90
  • Analyst Decision
  • NVO Strong Buy
  • NFLX Buy
  • Analyst Count
  • NVO 4
  • NFLX 32
  • Target Price
  • NVO $141.67
  • NFLX $1,025.41
  • AVG Volume (30 Days)
  • NVO 7.1M
  • NFLX 5.5M
  • Earning Date
  • NVO 05-07-2025
  • NFLX 04-17-2025
  • Dividend Yield
  • NVO 1.88%
  • NFLX N/A
  • EPS Growth
  • NVO 21.54
  • NFLX 64.84
  • EPS
  • NVO 3.14
  • NFLX 19.83
  • Revenue
  • NVO $40,314,376,667.00
  • NFLX $39,000,966,000.00
  • Revenue This Year
  • NVO $22.57
  • NFLX $15.85
  • Revenue Next Year
  • NVO $17.01
  • NFLX $11.99
  • P/E Ratio
  • NVO $21.79
  • NFLX $47.09
  • Revenue Growth
  • NVO 25.03
  • NFLX 15.65
  • 52 Week Low
  • NVO $69.18
  • NFLX $542.01
  • 52 Week High
  • NVO $148.15
  • NFLX $1,064.50
  • Technical
  • Relative Strength Index (RSI)
  • NVO 28.56
  • NFLX 45.30
  • Support Level
  • NVO $78.48
  • NFLX $966.32
  • Resistance Level
  • NVO $76.05
  • NFLX $998.70
  • Average True Range (ATR)
  • NVO 1.67
  • NFLX 29.13
  • MACD
  • NVO -0.97
  • NFLX 1.38
  • Stochastic Oscillator
  • NVO 13.70
  • NFLX 37.22

About NVO Novo Nordisk A/S

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

About NFLX Netflix Inc.

Netflix's relatively simple business model involves only one business, its streaming service. It has the biggest television entertainment subscriber base in both the United States and the collective international market, with more than 300 million subscribers globally. Netflix has exposure to nearly the entire global population outside of China. The firm has traditionally avoided a regular slate of live programming or sports content, instead focusing on on-demand access to episodic television, movies, and documentaries. The firm introduced ad-supported subscription plans in 2022, giving the firm exposure to the advertising market in addition to the subscription fees that have historically accounted for nearly all its revenue.

Share on Social Networks: